Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
NCT00368745
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Provide written informed consent
- 18-65 years old
- male and female
- A primary lifetime diagnosis of DSM-IV-TR (2000) GAD (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition)
- Pregnant or lactating women
- History of non-response to alprazolam, other benzodiazepines, gabapentin or pregabalin
given for the treatment of anxiety as indicated by a (screening or baseline) Hamilton
Anxiety Scale (HAM-A) score > 18
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New Haven, Connecticut
- New Haven, Connecticut
- Orlando, Florida
- Prairie Village, Kansas
- Birmingham, Alabama
- Litchfield Park, Arizona
- Arcadia, California
- Beverly Hills, California
- Costa Mesa, California
- Costa Mesa, California
- Encino, California
- Escondido, California
- Murrieta, California
- National City, California
- Newport Beach, California
- Orange, California
- Pasadena, California
- Redlands, California
- San Diego, California
- San Diego, California
- Sherman Oaks, California
- Temecula, California
- Upland, California
- Wildomar, California
- Denver, Colorado
- Hamden, Connecticut
- Norwich, Connecticut
- Altamonte Springs, Florida
- Ft. Myers, Florida
- Jacksonville, Florida
- Maitland, Florida
- Miami, Florida
- Miami, Florida
- Orange City, Florida
- Orlando, Florida
- South Miami, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Marietta, Georgia
- Libertyville, Illinois
- Naperville, Illinois
- Park Ridge, Illinois
- Greenwood, Indiana
- Terre Haute, Indiana
- Overland Park, Kansas
- Prairie Village, Kansas
- Wichita, Kansas
- Owensboro, Kentucky
- Lake Charles, Louisiana
- Baltimore, Maryland
- Belmont, Massachusetts
- Boston, Massachusetts
- Fall River, Massachusetts
- Haverhill, Massachusetts
- Pittsfield, Massachusetts
- Omaha, Nebraska
- Las Vegas, Nevada
- Nashua, New Hampshire
- Albuquerque, New Mexico
- Bronx, New York
- Brooklyn, New York
- New York, New York
- New York, New York
- New York, New York
- Rochester, New York
- Raleigh, North Carolina
- Columbus, Ohio
- Dayton, Ohio
- Toledo, Ohio
- Toledo, Ohio
- Bethany, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Portland, Oregon
- Salem, Oregon
- Allentown, Pennsylvania
- Media, Pennsylvania
- Norristown, Pennsylvania
- Philadelphia, Pennsylvania
- Lincoln, Rhode Island
- Columbia, South Carolina
- Memphis, Tennessee
- Memphis, Tennessee
- Austin, Texas
- Dallas, Texas
- Dallas, Texas
- DeSoto, Texas
- Houston, Texas
- Houston, Texas
- Lake Jackson, Texas
- San Antonio, Texas
- Woodstock, Vermont
- Charlottesville, Virginia
- Seattle, Washington
- Middleton, Wisconsin
- Waukesha, Wisconsin
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use. | |||
Official Title ICMJE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Pregabalin in Subjects With Generalized Anxiety Disorder (GAD) Switching From Benzodiazepine Therapy. | |||
Brief Summary | GAD subjects maintained on a stable dose of alprazolam for at least four weeks who meet eligibility criteria will be randomized to receive pregabalin vs matching placebo while simultaneously tapering off of alprazolam over 6 weeks. Subjects return weekly for assessment of safety/tolerability of pregabalin vs placebo as well as for assessment of anxiety and benzodiazepine withdrawal symptoms. Subjects successfully able to discontinue alprazolam, will continue 6 weeks of treatment with pregabalin vs placebo (free of benzodiazepine use). The efficacy and safety of pregabalin vs placebo for anxiety symptoms and ability to discontinue/remain free of alprazolam will be compared among pregabalin and placebo treated groups. Hypothesis is that a greater proportion of subjects will be successful in discontinuing and remaining free from benzodiazepines who were treated with pregabalin as compared to subjects treated with placebo. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE | Generalized Anxiety Disorder | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 108 | |||
Original Enrollment ICMJE | 80 | |||
Actual Study Completion Date ICMJE | August 2008 | |||
Actual Primary Completion Date | August 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 65 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Costa Rica, Czech Republic, France, Guatemala, Italy, Mexico, Spain | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00368745 | |||
Other Study ID Numbers ICMJE | A0081092 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | November 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |